Group 1 - The core viewpoint of the news highlights the recent performance of Emperor International Investment, which has seen a significant decline in its stock price and financial metrics, indicating potential challenges ahead for the company [2][3]. - As of April 2, the Hang Seng Index closed at 23,202.53 points, down 0.02%, while Emperor International Investment's stock price increased by 7.41% to HKD 0.029 per share, with a trading volume of 2.2 million shares [1]. - Over the past month, Emperor International Investment has experienced a cumulative decline of 10%, and a year-to-date decline of 40%, underperforming the Hang Seng Index by 15.69% [2]. Group 2 - Financial data shows that as of September 30, 2024, Emperor International Investment reported total revenue of HKD 33.534 million, a decrease of 55.43% year-on-year, and a net profit attributable to the parent company of -HKD 1.4311 million, down 193.74% year-on-year [2]. - The company's gross profit margin stands at 2.71%, with a debt-to-asset ratio of 21.08% [2]. - Currently, there are no institutional investment ratings for Emperor International Investment, and its price-to-earnings (P/E) ratio is 3.98, ranking fifth in the industry, which has an average P/E ratio of 12.42 [3]. Group 3 - Emperor International Investment is a Hong Kong-listed company focused on precision oncology and genetic testing, providing molecular diagnostic solutions and academic research services for clinical doctors, hospitals, cancer patients, and high-risk health groups [4]. - The company has developed genetic testing products for various types of tumors, including respiratory, digestive, breast, gynecological, urinary, and head and neck tumors, covering all stages of cancer management from early screening to dynamic monitoring [4]. - The company operates laboratories in Beijing and Guangzhou, adhering to strict quality management standards and achieving high scores in various assessments [4].
帝王国际投资（00928.HK）4月2日收盘上涨7.41%，成交6.32万港元